Niagen Bioscience, Inc. Total Assets
Niagen Bioscience, Inc. total assets. Based on the latest financial reports, Niagen Bioscience, Inc. (NAGE) holds total assets worth $106.59 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Niagen Bioscience, Inc. market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Niagen Bioscience, Inc. (2007–2025)
Total assets of Niagen Bioscience, Inc. from 2007 to 2025. This chart illustrates how Niagen Bioscience, Inc.'s total assets have evolved over time, based on quarterly financial data. See today's stock price for Niagen Bioscience, Inc. for real-time trading data and today's change.
Niagen Bioscience, Inc. - Asset Composition Analysis
Niagen Bioscience, Inc. Total Assets Breakdown (December 2025)
Niagen Bioscience, Inc. total assets breakdown as of December 2025. Niagen Bioscience, Inc.'s total assets of $106.59 Million consist of 91.0% current assets and 9.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 60.9% |
| Accounts Receivable | $9.74 Million | 9.2% |
| Inventory | $20.42 Million | 19.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $5.66 Million | 5.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Niagen Bioscience, Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore NAGE working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Niagen Bioscience, Inc.'s current assets represent 91.0% of total assets in 2025, a decrease from 100.0% in 2007.
- Cash Position: Cash and equivalents constituted 60.9% of total assets in 2025, down from 100.0% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is inventory at 19.2% of total assets.
Niagen Bioscience, Inc. Competitors by Total Assets
Key competitors of Niagen Bioscience, Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Nestle S.A.
SW:NESN
|
Switzerland | CHF128.38 Billion |
|
The Magnum Ice Cream Company N.V.
AS:MICC
|
Netherlands | €7.49 Billion |
|
COFCO Tunhe Sugar Co Ltd
SHG:600737
|
China | CN¥22.01 Billion |
|
The a2 Milk Company Ltd
AU:A2M
|
Australia | AU$1.96 Billion |
|
Lotus Health Group Co
SHG:600186
|
China | CN¥3.86 Billion |
|
Grupo Herdez S.A.B. de C.V
MX:HERDEZ
|
Mexico | MX$48.32 Billion |
|
Shandong Oriental Ocean Sci-Tech Co Ltd
SHE:002086
|
China | CN¥1.59 Billion |
|
Namchow Food Group (Shanghai) Co. Ltd.
SHG:605339
|
China | CN¥4.18 Billion |
Niagen Bioscience, Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.50 | 3.88 | 2.97 |
| Quick Ratio | 5.13 | 3.24 | 2.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $82.74 Million | $64.35 Million | $35.06 Million |
Niagen Bioscience, Inc. - Advanced Valuation Insights
This section examines the relationship between Niagen Bioscience, Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.89 |
| Latest Market Cap to Assets Ratio | 1.77 |
| Asset Growth Rate (YoY) | 55.8% |
| Total Assets | $106.41 Million |
| Market Capitalization | $187.96 Million USD |
Valuation Analysis
Above Book Valuation: The market values Niagen Bioscience, Inc.'s assets above their book value (1.77x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Niagen Bioscience, Inc.'s assets grew by 55.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Niagen Bioscience, Inc. (2007–2025)
The table below shows the annual total assets of Niagen Bioscience, Inc. from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $106.41 Million | +55.84% |
| 2024-12-31 | $68.28 Million | +24.22% |
| 2023-12-31 | $54.96 Million | +1.68% |
| 2022-12-31 | $54.06 Million | -6.54% |
| 2021-12-31 | $57.84 Million | +50.79% |
| 2020-12-31 | $38.36 Million | -4.69% |
| 2019-12-31 | $40.25 Million | -4.70% |
| 2018-12-31 | $42.23 Million | -32.67% |
| 2017-12-31 | $62.72 Million | +217.56% |
| 2016-12-31 | $19.75 Million | +5.35% |
| 2015-12-31 | $18.75 Million | +62.80% |
| 2014-12-31 | $11.52 Million | +28.15% |
| 2013-12-31 | $8.99 Million | -0.53% |
| 2012-12-31 | $9.03 Million | +44.09% |
| 2011-12-31 | $6.27 Million | -3.65% |
| 2010-12-31 | $6.51 Million | +82.54% |
| 2009-12-31 | $3.57 Million | -12.69% |
| 2008-12-31 | $4.08 Million | +703884.48% |
| 2007-12-31 | $580.00 | -- |
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulat… Read more